3,5-di(tert-butyldimethylsilyloxy)-4'-methoxybenzophenone | 441351-46-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-di(tert-butyldimethylsilyloxy)-4'-methoxybenzophenone
• 英文别名: [3,5-Bis[[tert-butyl(dimethyl)silyl]oxy]phenyl]-(4-methoxyphenyl)methanone
• CAS: 441351-46-8
• 化学式: C₂₆H₄₀O₄Si₂
• 分子量: 472.772
• InChiKey: XFHJEDJFFLSWJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.69
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-di(tert-butyldimethylsilyloxy)-4'-methoxybenzophenone 在 四丁基氟化铵 作用下， 以 四氢呋喃 为溶剂， 以93%的产率得到(3,5-Dihydroxyphenyl)-(4-methoxyphenyl)methanone
  参考文献：
  名称：

  Antineoplastic Agents. 465. Structural Modification of Resveratrol:  Sodium Resverastatin Phosphate

  摘要：

  As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI(50) = 0.01-0.001 mug/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.

  DOI：

  10.1021/jm010119y
• 作为产物：
  描述：

  3,5-二羟基苯甲醛 在 重铬酸吡啶 、 正丁基锂 、 4 A molecular sieve 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 46.25h， 生成 3,5-di(tert-butyldimethylsilyloxy)-4'-methoxybenzophenone
  参考文献：
  名称：

  Antineoplastic Agents. 465. Structural Modification of Resveratrol:  Sodium Resverastatin Phosphate

  摘要：

  As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI(50) = 0.01-0.001 mug/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.

  DOI：

  10.1021/jm010119y

文献信息

• Antineoplastic Agents. 465. Structural Modification of Resveratrol:  Sodium Resverastatin Phosphate
  作者：George R. Pettit、Matthew P. Grealish、M. Katherine Jung、Ernest Hamel、Robin K. Pettit、J.-Charles Chapuis、Jean M. Schmidt

  DOI：10.1021/jm010119y

  日期：2002.6.1

  As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI(50) = 0.01-0.001 mug/mL) against a minipanel of human cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.